PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1536.00 - 1565.00
1090.00 - 1784.00
46.2K / 155.6K (Avg.)
23.48 | 66.41
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-70.15%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-60.19%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-145.06%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-176.21%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-205.44%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-204.18%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-204.18%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-88.28%
Negative 10Y revenue/share CAGR while 4997.T stands at 33.36%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-88.28%
Negative 5Y CAGR while 4997.T stands at 33.36%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-47.59%
Negative 3Y CAGR while 4997.T stands at 27.06%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
100.00%
10Y OCF/share CAGR in line with 4997.T's 100.00%. Walter Schloss would see both as similarly efficient over the decade.
100.00%
5Y OCF/share CAGR is similar to 4997.T's 100.00%. Walter Schloss might see parallel cost profiles or expansions producing comparable cash flow.
No Data
No Data available this quarter, please select a different quarter.
94.08%
Net income/share CAGR at 50-75% of 4997.T's 182.40%. Martin Whitman might question if the firm’s product or cost base lags behind.
94.08%
5Y net income/share CAGR at 50-75% of 4997.T's 182.40%. Martin Whitman might see a shortfall in operational efficiency or brand power.
71.55%
Below 50% of 4997.T's 260.73%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
179.77%
3Y equity/share CAGR above 1.5x 4997.T's 24.88%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.60%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
89.37%
We show growth while 4997.T is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
24.71%
Positive asset growth while 4997.T is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
-0.96%
We have a declining book value while 4997.T shows 1.82%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
96.39%
Debt growth far above 4997.T's 8.42%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
-100.00%
Our R&D shrinks while 4997.T invests at 0.00%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-10.08%
We cut SG&A while 4997.T invests at 0.00%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.